Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice

American Journal of Pathology

Volumn 151, Issue 3, 1997, Pages 689-696

  Lattanzio, Giuseppe ^a   Libert, Claude ^b,c   Aquilina, Massimo ^b   Cappelletti, Manuela ^b   Ciliberto, Gennaro ^b   Musiani, Piero ^a   Poli, Valeria ^b,d  

^a UNIVERSITY OF CHIETI   (Italy)

^b IRBM   (Italy)

^c Laboratory for Molecular Biology ^*  (Belgium)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; PRISTANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; ASCITES FLUID; B LYMPHOCYTE DIFFERENTIATION; CELL SURVIVAL; CELL TRANSFORMATION; IMMUNOCYTOCHEMISTRY; INFLAMMATION; MALE; MALIGNANT TRANSFORMATION; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PLASMA CELL; PLASMACYTOMA; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ASCITES; B-LYMPHOCYTES; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; PLASMA CELLS; PLASMACYTOMA; TERPENES; TIME FACTORS;

EID: 0030929261     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Kishimoto T, Hirano T: Molecular regulation of B lymphocyte response. Annu Rev Immunol 1988, 6:485-512
2. Hirano T, Akira S, Taga T, Kishimoto T: Biological and clinical aspects of interleukin 6. Immunol Today 1990, 11:443-449
3. Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, Ciliberto G, Rodan GA, Costantini F: Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 1994, 13:1189-1196
4. Klein B: Cytokine, cytokine receptors, transduction signals, and oncogenesis in human multiple myeloma. Semin Hematol 1995, 32:4-19
5. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T: Autocrine generation and requirement of BSF-2/IL6 for human multiple myelomas. Nature 1988, 332:83-85
6. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R: Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989, 73:517-526
7. Zhang X-G, Gaillard J-P, Robillard N, Lu Z-Y, Gu Z-J, Jourdan M, Boiron JM, Bataille R, Klein B: Reproducible obtaining of human myeloma cell lines as a model for tumour stem cell study in human multiple myeloma. Blood 1994, 83:3654-3663
8. Bataille R, Jourdan M, Zhang XG, Klein B: Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989, 84:2008-2011
9. Nachbaur DM, Herold M, Maneschg A: Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann Hematol 1991, 62:54-58
10. Reibnegger G, Krainer M, Herold M, Ludwig H, Wachter H, Hubert H: Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Res 1991, 51:6250-6253
11. Klein B, Wijdenes J, Zhang X-G, Jourdan M, Boiron J-M, Brochier J, Liautard J, Merlin M, Clement C, Morel-Fournier B, Lu Z-Y, Mannoni P, Sany J, Bataille R: Murine anti-IL-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991, 78:1198-1204
12. Bataille R, Barlogie B, Lu ZY, Rossi J-F, Lavabre-Bertrand T, Beck T, Wijdenes J, Brochier J, Klein B: Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995, 86:685-691
13. Klein B, Zhang X-G, Lu Z-Y, Bataille R: Interleukin-6 in human multiple myeloma. Blood 1995, 85:863-872
14. Nordan RP, Potter M: A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. Science 1986, 233:566-569
15. Van Snick J, Vink A, Cayphas S, Uyttenhove C: Interleukin-HP1, a T cell-derived hybridoma growth factor that supports the in vitro growth of murine plasmacytomas. J Exp Med 1987, 165:641-649
16. Degrassi A, Hilbert DM, Rudikoff SA, Anderson OM, Potter M, Coon HG: In vitro culture of primary plasmacytomas requires stromal cell feeder layers. Proc Natl Acad Sci USA 1993, 90:2060-2064
17. Suematsu S, Matsusaka T, Matsuda T, Akira S, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T: Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 1992, 89:232-235
18. Hilbert DM, Kopf M, Mock BA, Köler G, Rudikoff S: Interleukin 6 is essential for in vivo development of B lineage neoplasm. J Exp Med 1995, 182:243-248
19. Potter M, and Wiener F: Plasmacytomagenesis in mice: model of neoplastic development dependent upon chromosomal translocations. Carcinogenesis 1992, 13:1681-1697
20. Hilbert DM, Shen M-Y, Rapp UR, Rudikoff S: T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors. Proc Natl Acad Sci USA 1995, 92:649-655
21. Potter M, Wax JS: Peritoneal plasmacytomagenesis in mice: comparison of different pristane dose regimens. J Natl Cancer Inst 1983, 71:391-395
22. Potter M: Genetics of susceptibility to plasmacytoma development in Balb/c mice. Cancer Surv 1984, 3:247-264
23. Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, Carelli M, Faggioni R, Fantuzzi G, Ghezzi P, Poli V: Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 1994, 180:1243-1250
24. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, Faggioni R, Luini W, Van Hinsberg V, Sozzani S, Bussolino F, Poli V, Ciliberto G, Mantovani A. Immunity 1997, 6:315-325
25. Dedera DA, Urashima M, Chauhan D, LeBrun DP, Bronson RT, Anderson AC: Interleukin-6 is required for pristane-induced plasma cell hyperplasia in mice. Br J Hematol 1996, 94:53-61
26. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, Epstein J: Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994, 84:3063-3070
27. Kawano MM, Mihara K, Huang N, Tsujimoto T, Kuramoto A: Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood 1995, 85:487-494
28. L. Cancer Res 1995, 55:2262-2265
29. DeMartis A, Bernassola F, Savino R, Melino G, Ciliberto G: Interleukin 6 receptor antagonists are potent inducers of human multiple myeloma cell death. Cancer Res 1996, 56:4213-4218
30. Lu ZY, Zhang XG, Rodriguez C, Wijdenes J, Gu ZJ, Morel-Fournier B, Harousseau JL, Bataille R, Rossi JF, Klein B: Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. Blood 1995, 85:2521-2527
31. Zhang XG, Gu ZJ, Lu ZY, Yasukawa K, Yancopoulos GD, Turner K, Shoyab M, Taga T, Kishimoto T, Bataille R, Klein B: Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J Exp Med 1994, 179:1337-1342
32. Hilbert DM, Migone T-S, Kopf M, Leonard WJ, Rudikoff S: Distinct tumorigenic potential of abl and rat in B cell neoplasia: abl activates the IL-6 signaling pathway. Immunity 1996, 5:81-89